highly significantp=0.0009
There was no decline in serum IL-1β levels after three months therapy with IVA/LUM ( Figure 2B ), and yet IVA/TEZ treatment resulted in a highly significant reduction in serum IL-1β (p=0.0009, Figure 2F ; compare 2B).
There was no decline in serum IL-1β levels after three months therapy with IVA/LUM ( Figure 2B ), and yet IVA/TEZ treatment resulted in a highly significant reduction in serum IL-1β (p=0.0009, Figure 2F ; compare 2B).